From Protagonist Nabs $40M, Eyes 1st Trial Of Oral Peptide In Gut Disease:

Dinesh Patel, CEO of Protagonist Therapeutics
Dinesh Patel, CEO of Protagonist Therapeutics

Dinesh Patel, CEO of Protagonist Therapeutics